• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Immatics N.V.

    11/14/24 6:32:45 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMTX alert in real time by email
    SC 13G 1 p24-3256sc13g.htm

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  )*
     

    Immatics N.V.

    (Name of Issuer)
     

    Ordinary Shares, nominal value €0.01 per share

    (Title of Class of Securities)
     

    N44445109

    (CUSIP Number)
     

    September 30, 2024

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. N4444510913GPages 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    10,000,000 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    10,000,000 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    10,000,000 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.7%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

    CUSIP No. N4444510913GPages 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Roderick Wong, M.D.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    10,000,000 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    10,000,000 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    10,000,000 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.7%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

    CUSIP No. N4444510913GPages 4 of 7 Pages

     

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Immatics N.V. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at Paul-Ehrlich-Straße 15, 72076 Tübingen, Federal Republic of Germany.

     

    Item 2(a). NAME OF PERSON FILING:

     

      This statement is filed by:

     

      (i)

    RTW Investments, LP ("RTW Investments"), a Delaware limited partnership, and the investment adviser to certain funds (the "RTW Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the RTW Funds; and

     

      (ii) Roderick Wong, M.D. ("Dr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.

     

    Item 2(c). CITIZENSHIP:

     

      RTW Investments is a Delaware limited partnership.  Dr. Wong is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Ordinary Shares, nominal value €0.01 per share (the "Shares").

     

     

    CUSIP No. N4444510913GPages 5 of 7 Pages

     

    Item 2(e). CUSIP NUMBER:
       
      N44445109

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:                                                                                           

     

    Item 4. OWNERSHIP:

     

       

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference. 

         
        The percentages set forth herein are calculated based upon 103,105,906 Shares outstanding as of June 30, 2024, as reported in Exhibit 99.1 to the Company’s Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on August 13, 2024.

     

     

    CUSIP No. N4444510913GPages 6 of 7 Pages

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      See Item 2.  The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein. RTW Master Fund Ltd., a RTW Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the Shares.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. N4444510913GPages 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: November 14, 2024

     

     

    RTW INVESTMENTS, LP
         
         
    By: /s/ Roderick Wong, M.D.  
    Name: Roderick Wong, M.D.  
    Title: Managing Partner  
         
         
         
    /s/ Roderick Wong, M.D.  
    RODERICK WONG, M.D.  
         

     

    Get the next $IMTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMTX

    DatePrice TargetRatingAnalyst
    5/28/2025$10.00Buy
    Deutsche Bank
    10/7/2024$19.00Overweight
    Piper Sandler
    11/2/2023Overweight
    Cantor Fitzgerald
    3/31/2023$12.00Buy
    Mizuho
    3/24/2023$16.00Buy
    Bryan Garnier
    7/15/2021$26.00 → $27.00Outperform
    SVB Leerink
    More analyst ratings

    $IMTX
    SEC Filings

    See more
    • SEC Form 6-K filed by Immatics N.V.

      6-K - Immatics N.V. (0001809196) (Filer)

      5/13/25 7:05:24 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Immatics N.V.

      SCHEDULE 13G/A - Immatics N.V. (0001809196) (Subject)

      5/12/25 10:44:45 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Immatics N.V.

      SCHEDULE 13G/A - Immatics N.V. (0001809196) (Subject)

      5/2/25 5:40:51 PM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $IMTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

      Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable objective responses up to >2.5 years IMA203 PRAME cell therapy one-time infusion in all melanoma patients shows cORR of 56%; mDOR of 12.1 months at mFU of 13.4 months; mPFS of 6.1 months; mOS of 15.9 months Cutaneous melanoma subgroup post-checkpoint inhibitor shows cORR of 50%, mDOR not reached at mFU of 16.7 months; mPFS of 6.0 months Uveal melanoma subgroup, including tebentafusp-refractory patients shows cORR of 67%, mDOR of 11.0 months at mFU of 13.4 months; mPFS o

      5/31/25 8:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immatics Announces First Quarter 2025 Financial Results and Business Update

      IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026IMA203 PRAME Cell Therapy: Phase 1b clinical trial ongoing with updated data in metastatic melanoma with substantially longer follow-up and additional uveal melanoma patients to be presented in an oral presentation at the 2025 ASCO Annual Meeting IMA203CD8 PRAME Cell Therapy (GEN2): Phase 1a clinical trial in solid tumors ongoing with next data update, including dose escalation and ovarian cancer data, planned in 2025IMA402 PRAME Bispecific: Phase 1a clinical trial in solid tumors ongoing with next data update at relevant dose lev

      5/13/25 7:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

      Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30 – June 3, 2025, in Chicago, Illinois. Updated data from the Phase 1b trial of IMA203 in patients with metastatic melanoma with substantially longer follow-up compared to the last presentation in October 2024, and including data fro

      4/23/25 10:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Deutsche Bank initiated coverage on Immatics N.V. with a new price target

      Deutsche Bank initiated coverage of Immatics N.V. with a rating of Buy and set a new price target of $10.00

      5/28/25 9:08:28 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Immatics N.V. with a new price target

      Piper Sandler initiated coverage of Immatics N.V. with a rating of Overweight and set a new price target of $19.00

      10/7/24 7:57:11 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Immatics N.V.

      Cantor Fitzgerald initiated coverage of Immatics N.V. with a rating of Overweight

      11/2/23 7:08:49 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Immatics Appoints Alise Reicin to Board of Directors

      Houston, Texas and Tuebingen, Germany, July 31, 2024 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company"))), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the appointment of Alise Reicin, M.D., to its Board of Directors. Alise Reicin is an experienced and expert pharmaceutical industry executive and leader who has led the development of multiple important new therapies, including Keytruda®. Dr. Reicin currently serves as the President and CEO of Tectonic Therapeutic and is also a member of the Board of Directors of Sana Biotechnology. She joins Immatics' Board of Directors as the Company

      7/31/24 7:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Memo Therapeutics AG appoints Paul Carter as Chairperson

      PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies                  Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a

      7/8/24 7:00:00 AM ET
      $IMTX
      $IRWD
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Levicept Appoints Eliot Forster as CEO

      Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

      11/30/23 4:00:00 AM ET
      $IMCR
      $IMTX
      $PLX
      $FSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $IMTX
    Financials

    Live finance-specific insights

    See more
    • Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

      Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metastatic melanoma patients with substantially enhanced maturity compared to the last data update in May 2024 and provides the first report on progression-free survival (PFS) and overall survival (OS)Based on the Phase 1b data, the Company will proceed directly to a registration-enabling Phase 3 trial Regulatory pathway and clinical trial design for IMA203 finalized following FDA Type D meetings and meeting with the Paul Ehrlich Institute (PEI); RP2D and CMC package confirmedIMA203 conti

      10/10/24 6:30:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

      Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET IMA203 data with focus on melanoma patients presented at the International Congress of the Society for Melanoma Research today, November 8 IMA203 GEN1 TCR cell therapy targeting PRAME – update on Phase 1a and Cohort A Continues to be well tolerated50% confirmed objective response rate (cORR) in melanoma patients treated at recommended Phase 2 dose; durability with some ongoing responses at >15 months and median duration of response not reached at a median follow-up of 14.4 monthsTargeted to enter registration-enabling Phase 2 trial in melanoma in 2024; discussions with FDA ongoing based on recently ob

      11/8/23 7:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME

      Company to host conference call today, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203 TCR-T monotherapy against PRAME Objective response rate (ORR): 64% (7/11) initial ORR at week 6 and 67% (6/9) confirmed ORR at month 3Median duration of response not reached at median follow-up time of 8.5 months at data cut-offObjective responses independent of solid tumor type at low, medium and high PRAME expression levels in checkpoint-refractory cutaneous melanoma, platinum-resistant ovarian cancer, uveal melanoma, head and neck cancer and synovial sarcomaCohort A IMA203 monotherapy TCR-T t

      5/2/23 7:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Immatics N.V.

      SC 13G - Immatics N.V. (0001809196) (Subject)

      11/14/24 1:28:33 PM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Immatics N.V.

      SC 13G - Immatics N.V. (0001809196) (Subject)

      11/14/24 6:32:45 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immatics N.V.

      SC 13G/A - Immatics N.V. (0001809196) (Subject)

      11/8/24 10:46:38 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care